Gamma Scintigraphy of a ¹²³I-Labelled N-(2-Hydroxypropyl)Methacrylamide Copolymer-Doxorubicin Conjugate Containing Galactosamine Following Intravenous Administration to Nude Mice Bearing Hepatic Human Colon Carcinoma

References

• Ashwell G., Morell A. G. The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. Adv. in Enzymol. (1974); 41: 99–128
   PubMedGoogle Scholar
• Cassidy J., Duncan R., Morrison G. J., Strohalm J., Plocova D., Kopecek J., Kaye S. B. Activity of N-(2-hydroxypro-pyl)methacrylamide copolymers containing daunomycin against a rat tumour model. Biochem. Pharmacol. (1989); 38: 875–379
   PubMed Web of Science ®Google Scholar
• Chytry V., Kopecek J., Leibnitz E., O'Hare K., Scarlett L., Duncan R. Copolymers of 6-o-methacryloyl-D-galactose and N-(2-hydroxypropyl)methacrylamide: Targeting to liver after intravenous administration to rats. New Polymeric Mat. (1987); 1: 21–28
   Google Scholar
• Duncan R., Cable H. C., Lloyd J. B., Rejmanova P., Kopecek J. Degradation of side-chains of N-(2-hydroxypropyl) methacrylamide copolymers by lysosomal thiol-proteinases. Bioscience Reps (1983a); 2: 1041–1046
   Web of Science ®Google Scholar
• Duncan R., Kopecek J., Rejmanova P., Lloyd J. B. Targeting of N-(2-hydroxypropyl)methacrylamide copolymers to liver by incorporation of galactose residues. Biochim. Biophys. Acta (1983b); 755: 518–521
   PubMed Web of Science ®Google Scholar
• Duncan R., Seymour L. C.W., Scarlett L., Lloyd J. B., Rejmanova P., Kopecek J. N-(2-Hydroxypropyl)methacrylamide copolymers with pendant galactosamine residues. Fate after intravenous administration to rats. Biochim. Biophys. Acta (1986); 880: 62–71
   PubMed Web of Science ®Google Scholar
• Duncan R. Drug-polymer conjugates : potential for improved chemotherapy. Anti-Cancer Drugs (1992); 3: 175–210
   PubMed Web of Science ®Google Scholar
• Duncan R., Seymour L. W., O'Hare K. B., Flanagan P. A., Wedge S., Ulbrich K., Strohalm J., Subr V., Spreafico F., Grandi M., Ripamonri M., Farao M., Suarato A. Preclinical evaluation of polymer-bound doxorubicin. J. Controlled Rel. (1992); 19: 331–346
   Google Scholar
• Duncan R., Vasey P. A., Kaye S. B., Cassidy J. Development of PK1, an HPMA copolymer doxorubicin conjugate. The CRC experience. Abstract from the EORTC Early Drug Development Meeting, Corfu, June, 22–241995, 60–61
   Google Scholar
• Flanagan P. A., Kopeckova P., Subr V, Kopecek J., Duncan R. Evaluation of antibody-N-(2-hydroxypropyl)methacrylamide copolymer conjugates as targetable drug-carriers. 2. Body distribution of anti-Thy 1.2 antibody, anti-transferrin receptor antibody B3/25 and transferrin conjugates in DBA2 mice and activity of conjugates containing daunomycin against L1210 leukaemia in vivo. J. Controlled Release (1992); 18: 25–38
   Web of Science ®Google Scholar
• Kopecek J., Rejmanova P., Chytry V. Polymers containing enzymarically degradable bonds. 1. Chymotrypsin catalyzed hydrolysis of p-nitroanilides of phenylalanine and tyrosine attached to side-chains of copolymers of N-(2-hydroxyppropyl)-methacrylamide. Makromol. Chem. (1981); 182: 799–809
   Web of Science ®Google Scholar
• O'Hare K. B., Hume I. C., Scarlett L., Duncan R. Evaluation of anticancer agents coupled to N-(2-hydroxypro-pyl)methacrylamide copolymers. Effect of galactose incorporation on interaction with hepatoma in vitro. Hepatology (1989); 10: 207–214
   PubMed Web of Science ®Google Scholar
• O'Hare K. B., Duncan R., Strohalm J., Kopeckova P., Kopecek J., Ulbrich K. Macromolecular prodrugs containing doxorubicin and melanocyte stimulating hormone in vitro and in vivo evaluation against murine melanoma. J. Drug Targeting (1993); 1: 217–230
   PubMed Web of Science ®Google Scholar
• Pimm M. V., Perkins A. C., Duncan R., Ulbrich K. Targeting of N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugate to the hepatocyte galactose-receptor in mice: Visualisation and quantification by gamma scintigraphy as a basis for clinical targeting studies. J. Drug Targeting (1993); 1: 125–131
   PubMed Web of Science ®Google Scholar
• Richardson A. P, Mountford P. J., Baird A. C., Heyderman E., Richardson T. C., Coakley A. J. An improved Iodogen method of labelling antibodies with 123I. Nucl. Med Commun. (1986); 7: 355–362
   PubMed Web of Science ®Google Scholar
• Rejmanova P., Kopecek J., Pohl J., Baudys M., Kostka V. Polymers containing enzymatically degradable bonds. 8. Degradation of oligopeptide sequences in N-(2-hydroxypropyl) methacrylamide copolymers by bovine spleen cathepsin B. Makromol. Chem. (1983); 184: 2009–2020
   Web of Science ®Google Scholar
• Rihova B., Bilej M., Vetvicka V, Ulbrich K., Strohalm J., Kopecek J., Duncan R. Biocompatibility of N-2-hydroxypropyl-methacrylamide copolymers containing adriamycin. Biomaterials (1989); 10: 335–342
   PubMed Web of Science ®Google Scholar
• Seymour L. W., Ulbrich K., Strohalm J., Duncan R. Pharmacokinetics of a polymeric drug carrier targeted to the hepatocyte galactose receptor. Brit. J. Cancer (1991); 63: 859–866
   PubMed Web of Science ®Google Scholar
• Seymour L. W., Ulbrich K., Styger P. S., Brereton M., Subr V., Strohalm J., Duncan R. Tumouritropism and anticancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Br. J. Cancer (1994); 70: 636–641
   PubMed Web of Science ®Google Scholar
• Virgolini I., Muller C., Klepetko W., Angelberger P., Bergmann H., O'Grady J., Sinzinger H. Decreased hepatic function in patients with hepatoma or liver metastasis monitored by a hepatocyte specific galactosylated radioligand. Br. J. Cancer (1990); 61: 937–941
   PubMed Web of Science ®Google Scholar
• Yeung T. K., Hopewell J. W., Rezzani G., Simmonds R. H., Seymour L. W., Duncan R., Bellini O., Grandi M., Spreafico F., Strohalm J., Ulbrich K. Reduced cardiotox-icity of doxorubicin administered in the form of N-(2-hydrox-ypropyl)methacrylamide conjugates: an experimental study in the rat. Cancer Chemother. Pharmacol. (1991); 29: 105–111
   PubMed Web of Science ®Google Scholar
• Watson S. A., Morris T. M., Crosbee D. M., Hardcastle J. D. A hepatic invasive human colorectal xenograft model. Eur. J. Cancer (1993); 29A: 1740–1745
   PubMed Web of Science ®Google Scholar